Page 93 - The Flying Publisher Guide to Hepatitis C Treatment

References | 93

Fan X, Mao Q, Zhou D, et al. High diversity of hepatitis C viral quasispecies is
associated with early virological response in patients undergoing antiviral
therapy. Hepatology 2009;50:1765-72.
Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in
patients treated for chronic hepatitis C. Nature 2010;464:405-8.
Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24
weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Gastroenterology 2008;135:451-8.
Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025
combined with PEG-IFN alpha2a significantly reduces viral load in
treatment naive hepatitis C patients. Hepatology 2009;49:1460-8.
Foster GR. Pegylated interferons for the treatment of chronic hepatitis C:
pharmacological and clinical differences between peginterferon alfa 2a and
peginterferon alfa 2b. Drugs 2010;70:147-65.
Fried M, Jensed D, Rodriguez-Torres M, et al. Improved sustained virological
response (SVR) rates with higher, fixed doses of peginterferon alfa-2a
(40KD) (PEGASYS®)plus ribavirin(RBV) (COPEGUS®) in patients with
„difficult-to-cure” characteristics. Hepatology 2006; 44(Suppl 1):314A.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for
chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.
Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients
and donors correlate with response to peg-interferon and ribavirin therapy
for recurrent hepatitis C. Gastroenterology 2010;139:1577-85.
Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C Virus Drug Resistance and
Immune-Driven Adaptations: Relevance to New Antiviral Therapy.
Hepatology 2009;49:1069-82.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C
treatment-induced viral clearance. Nature 2009;461:399-401.
Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management and treatment
of hepatitis C. Hepatology 2009;49:1335-74.
Gonzalez S. Management of recurrent hepatitis C following liver transplantation.
Gastroenterol Hepatol (NY) 2010;6:637-45.
Guedj J, Perelson AS. Second phase HCV RNA decline during telaprevir based
therapy increases with drug effectiveness: Implications for treatment
duration. Hepatology 2011;53:1801-8.
Gonzalez SA, Keeffe EB. Management of chronic hepatitis C treatment failures:
role of consensus interferon. Biologics 2009;3:141–50.
Guo L, Orrego M, Rodriguez-Luna H, et al. Living donor liver transplantation for
Hepatitis C-related cirrhosis: No difference in histological recurrence when
compared to deceased donor liver transplantation recipients. Liver Transpl
2006;12:560-5.
Gurusamy KS, Tsochatzis E, Xirouchakis E, et al. Antiviral therapy for recurrent
liver graft infection with hepatitis C virus. Cochrane Database Syst Rev
2010:CD006803.
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin
combination therapy in chronic hepatitis C: a randomized study of
treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.